Clinical trials: Glioma, Malignant
High Grade Glioma, BRAF V600E
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors.
- Conditions
- High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma
- Trial name
- BRAF (NCT03973918)
- Testing
- Encorafenib, Binimetinib, Research Bloods
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioma
A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant Glioma
The purpose of this trial is to show proof of concept that by blocking the Transforming Growth Factor-beta signaling pathway in patients with Glioblastoma, there will be clinical benefit.
- Trial name
- NCT01220271
- Testing
- LY2157299, Radiation, Temozolomide
- Where
- 10 sites in United States, Germany and 1 more
- Volunteers
- 75 people
- Sponsor
- Eli Lilly and Company
Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
This study will test an investigational drug called AZD1390 in combination with radiation therapy for the treatment of brain tumors. This is the first time AZD1390 is being given to patients.
- Conditions
- Recurrent Glioblastoma Multiforme, Primary Glioblastoma Multiforme, Brain Neoplasms, Malignant, Leptomeningeal Disease (LMD)
- Trial name
- NCT03423628
- Testing
- Radiation Therapy, AZD1390
- Where
- 11 sites in United States, Japan and 1 more
- Volunteers
- 159 people
- Sponsor
- AstraZeneca
Pancreatic Cancer, Breast Cancer
The Clinical Application Value of SPECT Imaging Targeting LRRC15 in Malignant Tumors
Here's a polished version of the text: "This project involves patients with high-expression LRRC15 malignant tumors who are either clinically suspected of or diagnosed with pancreatic cancer, breast cancer, lung cancer, ovarian…
- Conditions
- Pancreatic Cancer, Breast Cancer, Lung Cancer, Sarcoma
- Trial name
- NCT07651020
- Testing
- Specific SPECT imaging agents targeting LRRC15
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Carbon Ion Radiotheray, High-grade Glioma
Clinical Study of Carbon Ion Radiotherapy for High-grade Glioma
The objective is to use the advantages of heavy ion physical dosimetry and biology to improve the tumor control rate and long-term survival rate of high-grade glioma, reduce the occurrence of brain tissue radiation damage caused…
- Conditions
- Carbon Ion Radiotheray, High-grade Glioma, Heavy Ion Radiotherapy
- Trial name
- NCT06831773
- Testing
- Carbon ion combined with photon radiotherapy
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Gansu Wuwei Tumor Hospital
Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
A study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme in patients with histologically proven advanced malignant pleural mesothelioma (MPM), advanced peritoneal mesothelioma (in dose escalation cohort…
- Conditions
- Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma
- Trial name
- TRAP (NCT02029690)
- Testing
- ADI-PEG 20
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 85 people
- Sponsor
- Polaris Group
Glioma, Malignant
Monitoring of Patients With Diffuse Gliomas Using Circulating miRNAs
MicroRNAs are small non-coding RNAs involved in the post-transcriptional regulation of genes and, consequently, of intracellular signalling pathways that govern cellular behaviour (Komatsu et al., 2023).
- Trial name
- GliomiR (NCT06203496)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Caen
Brain Neoplasm
Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas
This study is planned to detect a dose-efficacy relationship between the chosen dose levels of MC506/1 and the extent and quality of fluorescence in the tumour core in patients with newly diagnosed malignant glioma.
- Trial name
- NCT02755142
- Testing
- Gliolan
- Volunteers
- 21 people
- Sponsor
- medac GmbH
Malignant Supratentorial Neoplasm, Recurrent Glioblastoma
Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide
This phase I trial studies the side effects and best dose of lonafarnib when given together with temozolomide and to see how well they work in treating patients with glioblastoma multiforme that is has come back or did not…
- Conditions
- Malignant Supratentorial Neoplasm, Recurrent Glioblastoma, Recurrent Gliosarcoma
- Trial name
- NCT00102648
- Testing
- Lonafarnib, Temozolomide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- M.D. Anderson Cancer Center
Brain Tumor, Central Nervous System Tumor
Temozolomide Plus Lomustine Followed by Radiation Therapy in Treating Patients With High-Grade Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006024
- Testing
- lomustine, temozolomide
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 32 people
- Sponsor
- Children's Oncology Group
Brain and Central Nervous System Tumors
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma
RATIONALE: Mibefradil dihydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT01480050
- Testing
- temozolomide, 3'-deoxy-3'-[18F]fluorothymidine, pharmacological study
- Where
- 7 sites in United States
- Volunteers
- 28 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recurrent High-Grade Gliomas, Progressive Low-Grade Gliomas
ZD6474 to Treat Advanced Brain Cancer in Patients
Background: In vivo experiments have documented the ability of ZD6474 to inhibit tumor growth in various preclinical tumor models.
- Conditions
- Recurrent High-Grade Gliomas, Progressive Low-Grade Gliomas, Malignant Gliomas
- Trial name
- NCT00272350
- Testing
- Steroids, ZD6474
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
Glioma
Post-operative Imaging in High Grade Glioma: is Management Influenced?
Magnetic resonance imaging (MRI) is likely to play an important role in the management of high grade glioma. Appropriate and timely neuroimaging in the follow up period is believed to be crucial in making subsequent management…
- Trial name
- PIGMI (NCT04738110)
- Testing
- MRI
- Where
- United Kingdom
- Volunteers
- 150 people
- Sponsor
- King's College Hospital NHS Trust
Benign Neoplasms, Brain, Brain Cancer
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
The purpose of this study is to determine the safety and utility of 5-aminolevulinic acid (ALA) for identifying your tumor during surgery. 5-ALA is not FDA approved at this time.
- Conditions
- Benign Neoplasms, Brain, Brain Cancer, Brain Neoplasms, Benign, Brain Neoplasms, Malignant
- Trial name
- NCT01445691
- Testing
- 5-ALA (Gliolan)
- Where
- 6 sites in United States
- Sponsor
- Constantinos Hadjipanayis
Recurrent High-grade Glioma
AsiDNA Children, Adolescents and Young Adults
HGG comprises diffuse midline gliomas (DMG), including diffuse infiltrating brainstem glioma (DIPG), characterised by histone gene mutations, as well as non-DM HGGs mainly in non-midline supratentorial areas, with distinct…
- Trial name
- AsiDNA (NCT05394558)
- Testing
- AsiDNA
- Where
- 10 sites in France
- Volunteers
- 8 people
- Sponsor
- Institut Curie
Glioblastoma Multiforme
AZD7451 for Recurrent Gliomas
Background: AZD7451 is a drug that may help interfere with brain tumor cell growth. It can prevent glioma cells from entering into normal brain tissue, and slow or stop the growth of additional tumors.
- Trial name
- NCT01468324
- Testing
- AZD7451
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Glioma of Brain
Pilot Immunotherapy Trial for Recurrent Malignant Gliomas
This human Phase I trial involves taking the patient's own tumor cells during surgical craniotomy, treating them with an investigational new drug (an antisense molecule) designed to shut down a targeted surface receptor protein…
- Trial name
- NCT01550523
- Testing
- IGF-1R/AS ODN, biodiffusion chamber
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Recurrent Malignant Glioma
A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I)
This is a phase I study to evaluate the safety and tolerability of IL13Rα2 Targeted Chimeric Antigen Receptor-T Cell in patients with Refractory or Recurrent Malignant Glioma and to evaluate the changes of AE incidence.
- Trial name
- NCT05540873
- Testing
- YYB-103
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- CellabMED
Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma
Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial
This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma
- Trial name
- NCT04320888
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- 174 sites in United States, Australia and 1 more
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and…
- Conditions
- Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT05857969
- Testing
- Functional Precision Medicine
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Florida International University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.